| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 18 Jun 2024 | 18 Jun 2024 |
| With reference to the above cited subject, and pursuant to Regulation 30 read with Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, (Listing Regulations), and based on the recommendation of the Audit Committee, the Board of Directors of the Company at their meeting held today, i.e. Tuesday, June 18, 2024, inter-alia, transacted the following business: 1. Approved the Notice of Postal Ballot recommending to the shareholders, for appointment of Mr. Viswanath Kompella, Promoter, as an advisor of the company. This is for your information and records. | ||
| Board Meeting | 20 May 2024 | 6 May 2024 |
| VIVO BIO TECH LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/05/2024 inter alia to consider and approve Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31 2024. With reference to above cited subject, we bring to your kind notice that the Board of Directors at their meeting held today i.e., Monday, May 20, 2024, inter-alia, Approved the Audited Standalone and Consolidated Financial Results of the company for the fourth quarter and year ended March 31, 2024. (As Per BSE Announcement dated on 20.05.2024) | ||
| Board Meeting | 12 Feb 2024 | 30 Jan 2024 |
| VIVO BIO TECH LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2024 inter alia to consider and approve the Un-audited Standalone and Consolidated Financial Results for the Third Quarter and Nine Months ended December 31 2023. Please be informed that the trading window of Vivo Bio Tech Limited shall remain closed for all Directors Promoters Designated Employees and Specified Connected Persons of the Company till February 14 2024 in view of the aforesaid Board Meeting. This is for your information and records. With reference to the above cited subject and our letter dated January 30, 2024, we bring to your kind notice that the Board of Directors of the Company at their meeting held today, i.e. Monday, February 12, 2024, inter-alia, transacted the following business: 1. Approved the Un-Audited Standalone & Consolidated Financial Results of the Company for the Third Quarter and Nine Months ended December 31, 2023. The meeting commenced at 06.00 p.m. and concluded at 07.15 p.m. This is for your information and records. (As per BSE Announcement Dated on 12/02/2024) | ||
| Board Meeting | 23 Jan 2024 | 23 Jan 2024 |
| Outcome of the Board Meeting - Intimation of Appointment of Mr. Vaishnavi Kiran Ayinampudi as the Company Secretary & Compliance Officer of the Company | ||
| Board Meeting | 14 Nov 2023 | 3 Nov 2023 |
| VIVO BIO TECH LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2023 inter alia to consider and approve the Un-Audited Financial Results of the Company for the Second Quarter and Half-Year ended September 30 2023 Vivo Bio Tech Limited has informed the exchange about the Outcome of Board Meeting for Approval Of Un-Audited Standalone & Consolidated Financial Statements Of The Company For The Second Quarter and Half Year Ended September 30, 2023 Vivo Bio Tech Limited has submitted with the exchange the Un-Audited Financial Results of the Company for the second quarter and half year ended September 30, 2023 (As Per BSE Announcement dated on 14.11.2023) Vivo Bio Tech Limited has submitted with the exchange the copies of Newspaper Publication for Un-Audited Financial Results of the Company for the secodn quarter and half-year ended September 30, 2023 (As Per BSE Announcement Dated on 16.11.2023) | ||
| Board Meeting | 21 Sep 2023 | 17 Sep 2023 |
| VIVO BIO TECH LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/09/2023 inter alia to consider and approve VIVO BIO TECH LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/09/2023 inter alia to consider and approve 1. Proposal for issuance of equity shares/warrants by way of a preferential allotment in accordance with the provisions of the SEBI (Issue of Capital and Disclosure Requirements) Regulations 2018 and the Companies Act 2013 as amended subject to such regulatory/ statutory approvals as may be required. 2. Convening of an Extra-Ordinary General Meeting or Postal Ballot process to seek approval of the shareholders in respect of the aforesaid proposal of preferential allotment as required. Vivo Bio Tech Limited has informed the exchange that with reference to the Companys letter dated September 17, 2023, the Board of Directors of the Company at their meeting held today, i.e. Thursday, September 21, 2023, inter-alia, transacted the following business: 1. Approval for engagement/appointment of Consultants or Intermediaries for the proposed issuance of Equity Shares/Warrants by way of a Preferential Allotment, in accordance with the provisions of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 and the Companies Act, 2013, as amended, subject to such regulatory/ statutory approvals as may be required. (As Per BSE Announcement dated on 21.09.2023) | ||
| Board Meeting | 31 Aug 2023 | 31 Aug 2023 |
| Vivo Bio Tech Limited has informed the exchange regarding the business items transacted and approved by the Board at its meeting held today i.e. on August 31, 2023 | ||
| Board Meeting | 7 Aug 2023 | 24 Jul 2023 |
| VIVO BIO TECH LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2023 inter alia to consider and approve Un-Audited Standalone and Consolidated Financial Results for the quarter ended June 30 2023 Vivo Bio Tech Limited has submitted with the exchange the outcome of Board Meeting held on August 07, 2023 for Approval of Un-Audited Standalone & Consolidated Financial Statements Of The Company For The Quarter Ended June 30, 2023 Vivo Bio Tech Limited has submitted with the exchange the Un-Audited Standalone & Consolidated Financial Results for the quarter ended June 30, 2023 (As per BSE Announcement Dated on 07/08/2023) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
